Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Other financing activities (2021 - 2024)

Opus Genetics (IRD) has disclosed Other financing activities for 3 consecutive years, with $172000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Other financing activities rose 1333.33% to $172000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $278000.0, a 112.21% increase, with the full-year FY2024 number at $232000.0, down 16.55% from a year prior.
  • Other financing activities was $172000.0 for Q4 2023 at Opus Genetics, up from $106000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.1 million in Q2 2021 to a low of $12000.0 in Q4 2022.
  • A 3-year average of $213333.3 and a median of $106000.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: tumbled 95.01% in 2022, then soared 1333.33% in 2023.
  • Opus Genetics' Other financing activities stood at $194000.0 in 2021, then crashed by 93.81% to $12000.0 in 2022, then skyrocketed by 1333.33% to $172000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Other financing activities are $172000.0 (Q4 2023), $106000.0 (Q3 2023), and $12000.0 (Q4 2022).